Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5mg 17 β-estradiol and 2.5mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms

Hormone replacement therapy (HRT) is the most effective treatment for vasomotor symptoms associated with menopause and may improve quality of life [1]. HRT is also effective for the prevention of postmenopausal osteoporosis [2]. Multiple HRT combinations are available. The individual drugs and their combination are important in determining their safety and efficacy. It is recognised that different progestogens [3], and estrogens have distinct properties. Guidelines recommend individualising and tailoring HRT according to symptoms and the need for prevention, as well as age, personal and family history, and the woman ’s preferences and expectations using the lowest effective dose of estrogen to treat these symptoms [1,4,5].
Source: Maturitas - Category: Primary Care Authors: Source Type: research

Related Links:

ConclusionsEpidemiological evidence is rather consistent suggesting that there is a positive association between HRT use and MD with the highest increase in MD among current users, and CEP users. Our results suggest that due to increase in MD and masking effect, current E  + P users may require additional screening procedures, shorter screening intervals, or using advanced imaging techniques.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Hormone replacement therapy may slightly improve overall survival in women who have undergone surgical treatment for EOC, but the certainty of the evidence is low. HRT may make little or no difference to quality of life, incidence of breast cancer, TIA, CVA and MI as the certainty of the evidence has been assessed as very low. There may be little or no effect of HRT use on progression-free survival. The evidence in this review is limited by imprecision and incompleteness of reported relevant outcomes and therefore the results should be interpreted with caution. Future well-designed RCTs are required as this is...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
From new employee entitlements to soap opera storylines, older women ’s health needs a bigger profileConnected as it is with ageing, it is not surprising that the menopause has a bad reputation. Even for women who have generally found their periods to be a nuisance, the cessation of the monthly cycle of egg production often comes as a shock. As well as the psychological impact of what used to euphemistically be called “the change”, the menopause brings with it symptoms for which a lot of women find themselves alarmingly unprepared – asmany readers told us when we invited them to share their stories....
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Menopause Health Women Television industry Feminism World news Science Work & careers Guardian Careers Money Media Society Life and style Source Type: news
Conclusions World population is aging and the increase in life expectancy is often unhealthy. In particular, musculoskeletal aging, which leads to sarcopenia and osteoporosis, has several causes such as changes in body composition, inflammation, and hormonal imbalance. Sarcopenia, osteoporosis, and more frequently, sarcopenic obesity are commonly associated with aging and frequently closely linked each other, often leading to the development of a frailty syndrome. Frailty syndrome favors an increased risk of loss function in daily activities, for cardiovascular diseases, cancers, falls, and mortality. As the number of eld...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Abstract Nowadays, postmenopausal women are largely undertreated. Analysis of conflicting results among different studies suggests that hormone replacement therapy (HRT) can prevent osteoporosis and cardiovascular disease in symptomatic, early postmenopausal women. In fact, climacteric symptoms are related to an increased risk of chronic conditions, including hypertension and cardiovascular disease. Different scientific societies have pointed out that patient selection, timing of initiation, and the choice of the type and dose of HRT used are the major determinants of the ultimate effect of HRT on women's health a...
Source: Climacteric - Category: Geriatrics Authors: Tags: Climacteric Source Type: research
Our panel this morning discussed the issues surrounding how the WHI results were interpreted and communicated to women and their health care providers. We recognize that hormones are not appropriate for all women, and look forward to hosting a future panel that highlights alternatives. The speakers have a variety of backgrounds and experiences (and genders), and we aim to promote diversity of voices. This was not normal breakfast conversation. Today was a jolting – and disruptive – talk about what happens to women’s bodies when they age. (Who knew that if you’re menopausal and you don’t take y...
Source: Disruptive Women in Health Care - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: blogs
CONCLUSIONS: Currently, there is insufficient high-quality evidence to inform women considering HRT after treatment for endometrial cancer. The available evidence (both the single RCT and non-randomised evidence) does not suggest significant harm, if HRT is used after surgical treatment for early-stage endometrial cancer. There is no information available regarding use of HRT in higher-stage endometrial cancer (FIGO stage II and above). The use of HRT after endometrial cancer treatment should be individualised, taking account of the woman's symptoms and preferences, and the uncertainty of evidence for and against HRT use. ...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Publication date: Available online 9 March 2018 Source:American Journal of Kidney Diseases Author(s): Kavitha Vellanki, Susan Hou Most women with dialysis-dependent chronic kidney disease (CKD) stage 5 (CKD stage 5D) are in the postmenopausal age group. Early menopause is reported for all CKD stages (stages 3-5D). The traditional definition of menopause is not applicable in CKD stage 5(D) because menses can resume with hormone replacement therapy or kidney transplantation. Treatment of vasomotor symptoms continues to be the primary indication for hormone replacement therapy, with no dosing studies done specifically for CK...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Conclusions: Female sex hormones are important for the preservation of lung function in middle aged women. The accelerated lung function decline with menopause is likely caused by decreasing estrogen levels.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Epidemiology Source Type: research
Authors: Gambacciani M, Biglia N, Cagnacci A, DI Carlo C, Caruso S, Cicinelli E, DE Leo V, Farris M, Gambera A, Guaschino S, Lanzone A, Paoletti AM, Russo N, Vicariotto F, Villa P, Volpe A Abstract In the last decade the risk benefits ratio of HRT has been reevaluated mainly in tens of cardiovascular risk. Present Consensus Statement is largely inspired by the Global Consensus on Menopausel Hormone Therapy in 2013 and 2016 by leading global menopause societies (The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society,...
Source: Minerva Ginecologica - Category: OBGYN Tags: Minerva Ginecol Source Type: research
More News: Estradiol | Hormone Replacement Therapy | Hormones | Men | Menopause | Orthopaedics | Osteoporosis | Primary Care | Women